MedTrace Logo

A Study to Evaluate the Efficacy of EQ-778 on Upper Respiratory Tract Health Status in Healthy Adults

NCT05835375 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 374

Last updated 2024-01-31

No results posted yet for this study

Summary

This study is a randomized, double-blind, Placebo Controlled study to evaluate the efficacy of 180 days administration of EQ-778 on upper respiratory tract health status in healthy adults

Conditions

Interventions

OTHER

EQ-778

1. capsule daily after breakfast (in case of no URTI episode); 2. capsules after breakfast (in case of URTI episode)

OTHER

Placebo

1. capsule daily after breakfast (in case of no URTI episode); 2. capsules after breakfast (in case of URTI episode)

Sponsors & Collaborators

  • Vedic Lifesciences Pvt. Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-08-02
Primary Completion
2024-04-26
Completion
2024-04-26

Countries

  • India

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05835375 on ClinicalTrials.gov